Evrenzo 100 mg Alternative – Renofix (Roxadustat) 100 mg Tablet | Everest Pharmaceuticals
Renofix 100 mg (Roxadustat) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Evrenzo (Astellas). It belongs to the HIF-prolyl hydroxylase inhibitor class and is used in anemia associated with chronic kidney disease in jurisdictions where authorized.
Active ingredient: Roxadustat
Strength: 100 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Product Overview
Renofix 100 mg Tablet by Everest Pharmaceuticals Ltd., Bangladesh contains Roxadustat. It is listed here as a same-ingredient branded option for people researching Evrenzo, a reference brand associated with Astellas. Renofix and Evrenzo must not be assumed to have identical formulations, approved indications or demonstrated bioequivalence. This page refers only to the 100 mg strength.
Renofix vs. Evrenzo – Originator / Reference Brand Comparison
Evrenzo is a widely recognized reference brand for Roxadustat associated with Astellas. Renofix is the Everest Pharmaceuticals product listed in this catalogue. The comparison identifies a shared active ingredient; the exact strength, dosage form, excipients, product registration and interchangeability must be checked for each marketed presentation. Reference-brand naming does not mean Renofix is manufactured by Astellas, approved by the same regulator or automatically substitutable. In particular, different formulations and release forms must not be treated as interchangeable.
Composition and Active Ingredient
Active ingredient: Roxadustat
Strength: 100 mg
Dosage form: Tablet
Pharmacological class: HIF-prolyl hydroxylase inhibitor
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh.
The complete inactive ingredient list and product-specific pack presentation require confirmation from the manufacturer’s current label.
Therapeutic Uses and Indications
Roxadustat is used in anemia associated with chronic kidney disease in jurisdictions where authorized. The applicable indication depends on the specific formulation, country authorization, diagnosis, biomarker results where relevant, and previous treatment. The information describes the generic medicine’s recognized therapeutic context; it does not independently verify every indication for the Everest product in every country. Only a specialist can establish whether the medicine is suitable for an individual patient.
Mechanism of Action – How Roxadustat Works
Roxadustat is a HIF-prolyl hydroxylase inhibitor. In general, it stabilizes hypoxia-inducible factors to promote erythropoietic response. The medicine’s effects depend on disease biology, dosing, combinations with other treatments and patient factors. Mechanism of action alone does not establish effectiveness for an individual patient or a particular unapproved use.
Dosage and Administration
The product contains 100 mg per tablet; this is not a recommended daily dose. A prescriber determines the appropriate regimen based on the indication, laboratory results, organ function, interactions and adverse effects. Follow the approved product leaflet for food instructions, missed doses, handling and treatment duration. Never adjust the dose or replace another brand or strength without medical authorization.
Contraindications
Do not use this medicine if a clinician has identified a contraindication, including known hypersensitivity to its ingredients where applicable. Additional restrictions vary by active ingredient, formulation, disease and pregnancy status. The complete contraindication list must be checked in the locally approved prescribing information before treatment.
Warnings and Precautions
Important precautions for Roxadustat include: hemoglobin changes, high blood pressure and thrombotic events. Patients should discuss liver or kidney disease, cardiac conditions, blood count abnormalities, pregnancy plans and concurrent treatments with the prescribing team. Depending on the medicine, regular laboratory testing, electrocardiograms, blood pressure checks or other monitoring may be necessary. The product’s official safety labeling governs specific requirements.
Possible Side Effects
The adverse-effect profile of Roxadustat varies by indication and combination regimen. Relevant potential adverse effects and serious risks include hemoglobin changes, high blood pressure and thrombotic events. Other symptoms can occur, and not everyone experiences the same effects. Seek prompt medical attention for severe, unexpected or rapidly worsening symptoms, and consult the current patient leaflet for urgent warning signs.
Drug Interactions
Prescription medicines, over-the-counter products, herbal supplements and certain foods can change the effectiveness or safety of Roxadustat. The interaction profile is ingredient-specific; a clinician or pharmacist should review all concurrent treatments before therapy. Never add, stop or change another medicine based solely on this online description.
Pregnancy, Fertility and Breastfeeding
Many anticancer and hematology medicines can harm a developing fetus or require specific contraception and breastfeeding precautions. People who are pregnant, planning pregnancy or breastfeeding should not start Roxadustat without specialist advice. Exact pregnancy testing, contraception duration and breastfeeding restrictions must be checked in the official labeling for this medicine.
Storage and Handling
Store the medicine according to the instructions on the actual Everest Pharmaceuticals pack, protecting it from unsuitable heat, humidity and light as directed. Keep it in its original packaging, away from children, and do not use expired or damaged packs. Some anticancer medicines require additional safe-handling precautions.
Why Is Renofix Listed as an Alternative to Evrenzo?
This listing helps customers identify an Everest Pharmaceuticals product containing Roxadustat while researching Evrenzo. The term alternative refers to the active ingredient and therapeutic context, not proof of identical regulatory status, bioequivalence or permission to substitute. Confirm the exact formulation and strength with the treating clinician and check the destination country’s medicine registration and import rules.
Manufacturer Information
Listed brand: Renofix
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Reference brand: Evrenzo
Reference company: Astellas
Generic ingredient: Roxadustat
Strength: 100 mg
Dosage form: Tablet
Therapeutic class: HIF-prolyl hydroxylase inhibitor
Frequently Asked Questions
What is Renofix 100 mg?
It is an Everest Pharmaceuticals tablet containing Roxadustat 100 mg.
Is Renofix the same as Evrenzo?
They are presented as brands associated with Roxadustat, but brand, formulation, approvals and product-specific evidence can differ. No automatic equivalence is established.
What is Roxadustat used for?
Roxadustat is used in anemia associated with chronic kidney disease in jurisdictions where authorized, subject to the applicable label and clinical assessment.
How does Roxadustat work?
It stabilizes hypoxia-inducible factors to promote erythropoietic response.
Can I switch strengths or brands myself?
No. A licensed prescriber or pharmacist must assess any substitution.
Is a prescription needed?
Yes. This medicine requires appropriate prescription and specialist oversight under applicable laws.
Important Medical Disclaimer
This page provides educational pharmaceutical identification information, not personal medical advice. Prescribing, dispensing and any substitution must be based on current authorized labeling, patient assessment and applicable laws. Product-specific registration and equivalence have not been independently established by this catalogue.
| Generic Name | Roxadustat |
|---|---|
| Strength | 100 mg |
| Dosage Form | Tablet |
| Manufacturer | Everest Pharmaceuticals Ltd. |
| Pack Size | 3 or 6 tablets; verify exact pack for each strength |
Related products
Lenvima 4 mg Alternative – Lenvaxen (Lenvatinib) 4 mg Capsule | Everest Pharmaceuticals
Lenvaxen 4 mg (Lenvatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lenvima (Eisai). It belongs to the multikinase inhibitor class and is used in selected thyroid, renal, liver and endometrial cancer regimens.
Active ingredient: Lenvatinib
Strength: 4 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Lorbrena / Lorviqua 100 mg Alternative – Lorbrexen (Lorlatinib) 100 mg Tablet | Everest Pharmaceuticals
Lorbrexen 100 mg (Lorlatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lorbrena / Lorviqua (Pfizer). It belongs to the ALK inhibitor class and is used in selected ALK-positive metastatic non-small cell lung cancer.
Active ingredient: Lorlatinib
Strength: 100 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Lumakras / Lumykras 120 mg Alternative – Sotoxen (Sotorasib) 120 mg Tablet | Everest Pharmaceuticals
Sotoxen 120 mg (Sotorasib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lumakras / Lumykras (Amgen). It belongs to the KRAS G12C inhibitor class and is used in selected KRAS G12C-mutated non-small cell lung cancer.
Active ingredient: Sotorasib
Strength: 120 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Retevmo / Retsevmo 40 mg Alternative – Selcaxen (Selpercatinib) 40 mg Capsule | Everest Pharmaceuticals
Selcaxen 40 mg (Selpercatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Retevmo / Retsevmo (Eli Lilly). It belongs to the RET inhibitor class and is used in selected RET-altered lung or thyroid cancers.
Active ingredient: Selpercatinib
Strength: 40 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Tagrisso 80 mg Alternative – Osimert (Osimertinib) 80 mg Tablet | Everest Pharmaceuticals
Osimert 80 mg (Osimertinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Tagrisso (AstraZeneca). It belongs to the EGFR tyrosine kinase inhibitor class and is used in selected EGFR-mutated non-small cell lung cancer.
Active ingredient: Osimertinib
Strength: 80 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Talzenna 1 mg Alternative – Talaparib (Talazoparib) 1 mg Capsule | Everest Pharmaceuticals
Talaparib 1 mg (Talazoparib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Talzenna (Pfizer). It belongs to the PARP inhibitor class and is used in selected genetically defined breast and prostate cancer treatment settings.
Active ingredient: Talazoparib
Strength: 1 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Votrient 200 mg Alternative – Pazorest (Pazopanib) 200 mg Tablet | Everest Pharmaceuticals
Pazorest 200 mg (Pazopanib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Votrient (Novartis). It belongs to the multitarget kinase inhibitor class and is used in selected advanced renal cell carcinoma and soft tissue sarcoma.
Active ingredient: Pazopanib
Strength: 200 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Zejula 100 mg Alternative – Niranib (Niraparib) 100 mg Capsule | Everest Pharmaceuticals
Niranib 100 mg (Niraparib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Zejula (GSK). It belongs to the PARP inhibitor class and is used in selected ovarian cancer maintenance treatment settings.
Active ingredient: Niraparib
Strength: 100 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Reviews
There are no reviews yet.